Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)
Public ClinicalTrials.gov record NCT00288704. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
IL1T-AI-0505: A Multi-center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, & Efficacy of Rilonacept in Subjects With Cryopyrin-Associated Periodic Syndromes (CAPS) Using Parallel Group & Randomized Withdrawal Designs
Study identification
- NCT ID
- NCT00288704
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Enrollment
- 104 participants
Conditions and interventions
Conditions
Interventions
- rilonacept 160 mg Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 7 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2005
- Primary completion
- May 31, 2008
- Completion
- Jul 31, 2008
- Last update posted
- Dec 5, 2011
2005 – 2008
United States locations
- U.S. sites
- 24
- U.S. states
- 19
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72204 | — |
| Not listed | Palm Desert | California | 92260 | — |
| Not listed | Upland | California | 91786 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Stuart | Florida | 34996 | — |
| Not listed | Atlanta | Georgia | 30342 | — |
| Not listed | Columbus | Georgia | 31904 | — |
| Not listed | Aurora | Illinois | 60504 | — |
| Not listed | Louisville | Kentucky | 40215 | — |
| Not listed | Shreveport | Louisiana | 71105 | — |
| Not listed | Chesterfield | Michigan | 48047 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | New York | New York | 10023 | — |
| Not listed | Raleigh | North Carolina | 27609 | — |
| Not listed | Cincinnati | Ohio | 45236 | — |
| Not listed | Duncansville | Pennsylvania | 16635 | — |
| Not listed | Columbia | South Carolina | 29201 | — |
| Not listed | Greer | South Carolina | 29651 | — |
| Not listed | Chattanooga | Tennessee | 37403 | — |
| Not listed | Dallas | Texas | 75235 | — |
| Not listed | Waco | Texas | 76712 | — |
| Not listed | Cedar City | Utah | 84720 | — |
| Not listed | Forest | Virginia | 24551 | — |
| Not listed | Lakewood | Washington | 98499 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00288704, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2011 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00288704 live on ClinicalTrials.gov.